001 < P < 0.01 (denoted by **) corresponds to very significant, 0.01 < P < 0.05 (denoted by *) corresponds to significant, and P > 0.05 is not significant (ns). The overall sensitivity of anti-E1E2 antibodies for the prediction of treatment response was calculated using receiver operating characteristic (ROC) curves in one-point studies Deforolimus mw and at different time points before and during treatment in follow-up studies. Optimal cutoff values were defined using the highest sum of sensitivity and specificity. For each optimal cutoff value, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Five negative controls (NHS) were initially tested at different dilutions:

1/50, 1/100, 1/250, 1/500, and 1/1000 (Fig. 1A). Standard dilutions selected were 1/250 and 1/500. The cutoff values for both dilutions were determined with 17 NHS (negative KU-60019 ic50 for HCV, HBV, and HIV; Fig. 1B). The mean OD values for E1, E2A, and E2B were 0.609 ± 0.033 for 1/250 dilution and 0.374 ± 0.036 for 1/500 dilution. The cutoff was calculated as the mean value + 3 SD, and corresponded to 0.708 for the 1/250 dilution and 0.482 for the 1/500 dilution. Each serum sample was tested in triplicate for the E1, E2A, and E2B peptides. For an easier representation of results, they were expressed as the average of OD obtained for E1, E2A,

and E2B, which are very similar (Fig. 1B). The interpretation for the presence or absence of anti-E1E2A,B antibodies took place according to these mean OD values. If the mean value was greater than or equal to the cutoff for a fixed dilution, the sample was defined as positive or the limit for this dilution.

If it was under the cutoff, the sample was considered negative. All the sera positive for anti-E1E2A,B contain antibodies that bind to the D32.10 epitope, i.e., to the three peptides, E1, E2A, and E2B. Inversely, the negative sera do not contain any of them. Therefore, these antibodies are called “D32.10 epitope-binding antibodies” throughout the text. At least five NHS were systematically included in each assay, and the selleck kinase inhibitor cutoff was recalculated for each type of experiments. The intra-assay variability was evaluated by testing a same positive sample 10 times in an intra-assay run, and showed a coefficient of variation < 4%. The inter-assay variability was evaluated by testing a same positive sample in triplicate in seven independent runs at different days by the same technician, and showed a coefficient of variation < 5%. Figure 2A shows the results obtained with samples from 52 patients cured of HCV infection (Group 1: C). Twenty-two patients who had spontaneously cleared a past infection (≥10 years) corresponded to the series 1, whereas the 30 other patients whose date of acute infection was unknown corresponded to the series 2. Among the total of 52 C patients, 46 were found positive for anti-E1E2A,B antibodies (88.5%) with a higher prevalence (21 of 22, 95.5%) in the series 1.